By Professor Alan Trounson (Cartherics)2023-11-17T16:00:37
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2023-02-03T13:56:13
Sponsored by Leica Microsystems
2023-02-13T11:57:11
Sponsored by Agilent
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2023-02-07T15:25:20
Sponsored by Bio-Techne
2024-01-19T07:40:55
Sponsored by Euretos
Site powered by Webvision Cloud